Document Detail

Oxprenolol slow-release with cyclopenthiazide KCl in the treatment of essential hypertension. A multicentre general practice study.
MedLine Citation:
PMID:  7015537     Owner:  NLM     Status:  MEDLINE    
In part I of this article we report on 89 hypertensive patients who underwent 9 months of treatment with oxprenolol HCl 160 mg in a slow-release formulation plus cyclopenthiazide 0.25 mg and potassium chloride 600 mg (Trasidrex; Ciba-Geigy). Blood pressures, both supine and standing, and pulse rates were consistently controlled by this regimen throughout the 9 months of treatment, regardless of the time of day at which these parameters were measured, i.e. morning or afternoon. Seventy-six patients completed the trial. The most common symptom or sign occurring during treatment was headache, the next most common being heartburn. No patient developed angina while on the regimen. Three patients discontinued the study owing to unwanted effects. This study represents a total of 28237 patient-days of treatment. In part II of the trial we studied the effects of a similar regiment in 67 patients for 1 year preceded by a 2-week wash-out period. Forty-six of the patients completed a full year's treatment. Statistically significant reductions in blood pressures and pulse rates occurred after commencement of active treatment and were maintained throughout the study period. Four patients withdrew from the study owing to adverse effects, 1 patient died of an acute myocardial infarction, and 1 patient was considered a treatment failure. This study represents 19858 patient-days of treatment.
J H Levenstein
Related Documents :
18763247 - Exposure of the elderly to potential nephrotoxic drug combinations in belgium.
16760697 - Prognosis and mechanism of death in treated heart failure: data from the placebo arm of...
20889997 - Use of propranolol in infantile haemangioma among chinese children.
11378007 - Systematic review of the impact of beta blockers on mortality and hospital admissions i...
21320087 - Comparison of blind tracheal intubation through the intubating laryngeal mask airway (l...
19839167 - Erbium:yag laser resurfacing in patients with inflamed cystic acne.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde     Volume:  59     ISSN:  0256-9574     ISO Abbreviation:  S. Afr. Med. J.     Publication Date:  1981 Jun 
Date Detail:
Created Date:  1981-07-20     Completed Date:  1981-07-20     Revised Date:  2014-09-12    
Medline Journal Info:
Nlm Unique ID:  0404520     Medline TA:  S Afr Med J     Country:  SOUTH AFRICA    
Other Details:
Languages:  eng     Pagination:  893-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects
Circadian Rhythm
Clinical Trials as Topic
Cyclopenthiazide / administration & dosage*
Delayed-Action Preparations
Drug Combinations
Drug Therapy, Combination
Hypertension / drug therapy*
Middle Aged
Oxprenolol / administration & dosage*
Patient Dropouts
Potassium Chloride / administration & dosage*
Pulse / drug effects
Sodium Chloride Symporter Inhibitors / administration & dosage*
Time Factors
Reg. No./Substance:
0/Delayed-Action Preparations; 0/Diuretics; 0/Drug Combinations; 0/Sodium Chloride Symporter Inhibitors; 519MXN9YZR/Oxprenolol; 660YQ98I10/Potassium Chloride; VX4S2N85F5/Cyclopenthiazide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Penbutolol and furosemide in a fixed-dose combination-bio-equivalence of two formulations.
Next Document:  Indapamide in a single daily dose in the treatment of hypertension. A multicentre trial in private p...